Ushio Inc. · TSE:6925
Ushio — Q3 FY2015 Earnings Presentation
23 slides from Ushio's earnings presentation, Jan 29, 2016
Slide 1: 3rd Quarter FY2015 Financial Results
3rd Quarter FY2015 Financial Results USHIO INC. Jan. 29, 2016 This report contains forward-looking statements, including earnings forecasts, which are based on information currently available to the Company and on certain assumptions deemed to be reasonable. Please be advised that actual results may
Slide 2: Agenda
I. Financial Results for 3Q FY2015 II. Forecasts for FY2015 III. Supplementary Information 2
Slide 3: Highlights of Financial Results for 3Q FY2015
Highlights of Financial Results for 3Q FY2015 Consolidated net sales up 17.2% year on year to ¥134.5 billion Consolidated operating income up 64.7% year on year to ¥10.5 billion - Full-year targets unchanged: ¥180.0 billion in net sales and ¥13.0 billion in operating income - Y0Y YoY ＋23.6% ＋24% Equ
Slide 4: Summary of Financial Results 3Q FY2015
Summary of Financial Results 3Q FY2015 FY14 FY15 YoY FY14 FY15 YoY (Billions of yen) 1-3Q 1-3Q Changes ％ 3Q 3Q Changes ％ Net Sales 114.8 134.5 +19.7 +17.2 40.4 45.9 +5.4 +13.6 Operating Income 6.3 10.5 +4.1 +64.7 2.3 3.9 +1.6 +67.5 Operating Income Ratio (%) 5.6 7.8 +2.3P - 5.9 8.6 +2.8P - Ordinary
Slide 5: Financial Results Trend (Quarterly Comparison)
Financial Results Trend 《Quarterly Comparison》 QoQ (Billions of Yen) 1Q 2Q 3Q Changes ％ Net Sales 41.1 47.4 45.9 ▲1.5 ▲3.3 Operating Income 2.3 4.2 3.9 ▲0.2 ▲5.4 Operating Income Ratio (%) 5.7 8.8 8.6 ▲0.2P - Ordinary Income 3.3 4.2 5.5 +1.2 +29.4 Profit Attributable to Owners of Parent 2.6 2.8 4.0
Slide 6: Financial Results by Business Segments
Financial Results by Business Segments (Billions of Yen) FY14 FY15 YoY FY14 FY15 YoY Business Segments 1-3Q 1-3Q Changes ％ 3Q 3Q Changes ％ Equipment Net Sales 59.9 74.1 +14.1 +23.6 21.2 26.2 +5.0 +23.6 Operating Income ▲0.3 1.6 +2.0 - 0.0 1.1 +1.0 +1196.6 Operating Income Ratio (%) ▲0.6 2.2 +2.8P -
Slide 7: Equipment Business Segment Net Sales
Equipment Business Segment 《Net Sales》 《1-3Q ttl》 Net Sales Changes(%) Imaging (Billions of Yen) 74.1 ＋ 23.6 On a YoY basis, sales in the cinema field rose by 59.9 1.3 nearly 50%, while sales in the general imaging Illumination ▲ 14.4 field were held to a 14% increase. On a QoQ 1.6 basis, sales in t
Slide 8: Light Sources Business Segment Net Sales
Light Sources Business Segment 《Net Sales》 《1-3Q ttl》 Net Sales Changes(%) (Billions of Yen) 58.2 Discharge +11.0 52.5 On a YoY basis, sales of cinema lamps rose 10%, while sales of solid state light sources doubled, reflecting the positive impact of an Discharge acquisition. Sales of both these pro
Slide 9: Forecasts for FY2015
I. Financial Results for 3Q FY2015 II. Forecasts for FY2015 III. Supplementary Information 9
Slide 10: FY2015 Progress Rate
FY2015 Progress Rate (Billions of Yen) 1-3Q Progress Rate FY15 (against FY15 Forecast) (Forecast) Net Sales 134.5 74.8 180.0 Operating Income 10.5 80.9 13.0 Operating Income (%) 7.8 - 7.2 Ordinary Income 13.0 87.2 15.0 Profit Attributable to Owners of Parent 9.5 81.0 12.0 EPS (Yen) 73.81 - 91.91 ROE
Slide 11: Forecasts for FY2015 Net Sales
Forecasts for FY2015 《Net Sales》 FY15 Progress Rate (Billions of Yen) 1-3Q (against FY15 Forecast) FY2015 Forecast (Forecast) DCP shipments are expected to be Equipment Imaging equipment 75.0 54.8 73.1 slightly above the initial forecast of 4,000 units. Shipments of lithography tools for electronic
Slide 12: Main Upside and Downside Factors by Product for FY2016 Onward
Reference: Main Upside and Downside Factors by Product for FY2016 Onward Main Upside Factors Main Downside Factors UV lamps Increase in the number of lithography runs in the Oversupply, falling prices, and extended use of LCD OLED lithography process panels Increase in demand for semiconductors driv
Slide 13: Supplementary Information
I. Financial Results for 3Q FY2015 II. Forecasts for FY2015 III. Supplementary Information 13
Slide 14: Sales Trend by Product Groups (Quarterly Transition)
Sales Trend by Product Groups 《Quarterly Transition》 （Billions of yen） 47.4 45.9 44.5 0.8 Equipment 0.6 Business 40.4 1.0 41.1 0.5 45.0 39.9 0.2 0.7 0.7 0.6 0.8 34.4 0.5 0.5 0.8 26.6 26.2 0.6 18.5 (56.2%) 20.1 (57.1%) 0.2 16.9 24.0 21.2 14.0 (54.0.%)16.2 30.0 21.9 17.5 21.2 (51.6.%) 11.9 (55.0%) (52
Slide 15: Foreign Sales Ratio (1-3Q)
Foreign Sales Ratio 《1-3Q》 ◆FY14 Others, ◆FY15 Others, 1.9% 1.3% Europe, Japan, Europe, Japan, 14.3% 18.4% 11.7% 19.6% Net Sales Net Sales 114.8 134.5 (Billions North Asia, (Billions Asia, of Yen) 35.8% of Yen) North America, America, 36.9% 28.5% 31.6% 15
Slide 16: Non-Operating Income and Expenses (1-3Q)
Non-Operating Income and Expenses《1-3Q》 (Billions of Yen) FY14 FY15 YoY Non-Operating Income 3.1 2.9 ▲0.2 Interest income 0.5 0.5 +0.0 Dividend income 1.0 1.1 +0.1 Foreign exchange gains 0.7 0.7 +0.0 Realized and unrealized profit on trading securities, net 0.4 0.1 ▲0.2 Gain on sales of investment s
Slide 17: Balance Sheet
Balance Sheet ◆ Asset s ◆ Liabilities・Total Net Assets (Billions of Yen) Changes (Billions of Yen) Changes 294.5 306.1 + 11.6 294.5 306.1 + 11.6 20.0 + 2.2 Notes and Accounts Payable 17.7 66.7 34.2 60.7 + 6.0 Cash and Bank Deposits 27.0 + 7.1 Other Current Liabilities Notes and Accounts 29.9 ▲1.0 Lo
Slide 18: Cash Flow
Cash Flow (Billions of yen) 15.0 Investing Activities 11.0 10.2 Financing Activities 6.9 7.0 6.2 4.3 Free Cash Flow 3.0 0.2 -1.0 ▲ 2.5 ▲ 2.5 Operating Activities -5.0 ▲ 4.0 FY14 FY15 Cash and Cash Equivalents Cash and Cash Equivalents at the Beginning of the FY 45.3 at the Beginning of the FY 56.9 C
Slide 19: Capital Expenditures, Depreciation and Amortization, R&D Expenses
Capital Expenditures, Depreciation and Amortization, R&D Expenses ◆Capital Expenditures, ◆ R&D Expenses Depreciation and Amortization Capital Expenditures Depreciation and Amortization R&D Expenses Actual Actual Actual 1-3Q 1-3Q 1-3Q Plan Plan Plan (Billions of Yen) (Billions of Yen) 12.5 15.0 10.8
Slide 20: TOPICS USHIO
TOPICS 20 USHIO
Slide 21: Risk Testing Service Business and Handheld UV Phototherapy Device
Launch of Handheld Version of Start of Risk Testing Service Business Ultraviolet Phototherapy Device Announced on Jan 14, 2016 Announced on Jan 20, 2016 × × × Ushio Inc., Biomarker Science Co., Ltd. On February 1, 2016, Ushio launched “TheraBeam® and Protosera Inc. joined hands to start UV308 mini”
Slide 22: Christie to Sell Matrix Product Lines to Rockwell Collins
Christie to Sell Matrix Product Lines to Rockwell Collins Announced on Jan 26, 2016 Christie Digital Systems (hereinafter CDS), 100% subsidiary of Ushio Inc., had entered into an agreement to sell the assets of the Matrix series for military simulation to Rockwell Collins (hereinafter RC) to focus
Slide 23: Contact: Corporate Communication Department, USHIO INC.
Contact: Corporate Communication Department, USHIO INC. Email: [email protected] http://www.ushio.co.jp/global/ 23